CNCK
Coincheck Group N.V.
There isn't enough reported data to score CNCK yet.
JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
CNCK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| N/A | |
| N/A |
CNCK's revenue is currently healthy, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNCK.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
CNCK PE Valuation
CNCK has no meaningful PE right now: it lost money over the past year.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
CNCK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Stable | |
| Limited | |
| Low |
Analysts expect CNCK's losses to grow, with revenue declining. However, they disagree widely on these estimates.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
JPM has the edge over CNCK on the outlook, with more favorable earnings and revenue expectations.
CNCK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.06 | +$0.71 |
| Q1 2026 | -$0.09 | +$0.33 |
| Q4 2025 | -$0.00 | -100% |
| Q3 2025 | -$0.76 | -142% |
| Q2 2025 | -$0.77 | -145% |
| Q1 2025 | -$0.42 | -134% |
| Q4 2024 | $0.77 | +1825% |
| Q1 2022 | $16.51 | -60% |
CNCK is still losing money, but far less than before: $0.06 per share over the past year, against $0.77 at its worst in mid-2025.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over CNCK on earnings quality, reporting a profit while its opponent remains loss making.
CNCK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $716.6M | +36% |
| Q1 2026 | $750.3M | +4.5% |
| Q4 2025 | $899.2M | +17% |
| Q3 2025 | $834.3M | +89% |
| Q2 2025 | $526.4M | +12% |
| Q1 2025 | $718.2M | +13% |
| Q4 2024 | $771.6M | +108% |
| Q3 2024 | $440.9M | +88% |
CNCK has the edge over JPM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1.2% | -0.2 points |
| Q1 2026 | -1.2% | -1.1 points |
| Q4 2025 | 0.6% | +13 points |
| Q3 2025 | 0.7% | +0.7 points |
| Q2 2025 | -1% | -1.9 points |
| Q1 2025 | 0% | -2.4 points |
| Q4 2024 | -12% | -14 points |
| Q3 2024 | 0% | +0.3 points |
CNCK's operating margin was −1.2% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2020.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over CNCK on profitability, with a higher operating margin.
CNCK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.1M | -277% |
| Q1 2026 | -$2.9M | +$9.1M |
| Q4 2025 | $12.2M | +$16.3M |
| Q3 2025 | -$8.5M | -$3.5M |
| Q2 2025 | $5.2M | +11% |
| Q1 2025 | -$12M | -204% |
| Q4 2024 | -$4.1M | -149% |
| Q3 2024 | -$4.9M | -995% |
CNCK's free cash flow was −$8M over the past year, against −$16M the year before. Free cash flow isn't a meaningful measure for financial services companies like CNCK.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM has the edge over CNCK on cash flow, with more consistent year-over-year improvement.
CNCK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +41% | +56M shares |
| 1 year | +47% | +61M shares |
| 3 years | +1803% | +182M shares |
| 5 years | +9519% | +190M shares |
CNCK has 192M diluted shares, up 47% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over CNCK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
CNCK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 85.4x | High |
| Q1 2026 | -66.8x | Net Cash |
| Q3 2024 | 0.0x | Very low |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | 9.9x | High |
| Q4 2023 | -2,695.0x | Net Cash |
| Q4 2022 | 0.0x | Very low |
| Q3 2022 | -5.3x | Net Cash |
CNCK's net debt is more than 20 years of its operating earnings (EBITDA), up from 9.9 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CNCK.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM has the edge over CNCK on leverage, with a lower net debt burden relative to earnings.
CNCK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.0 | Neutral |
| Stochastic | 2.8 | Oversold |
CNCK's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
CNCK PE vs Financial Services Sector
CNCK has no meaningful PE right now: it lost money over the past year.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
CNCK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 17% below |
| 20 week MA | $1.85 | 41% below |
| 50 week MA | $2.17 | 49% below |
| 100 week MA | $4.03 | 73% below |
JPM has stronger trend alignment. CNCK is above 0 of 4 weekly averages versus JPM above 4 of 5.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
CNCK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $13.9 | $8.50 | -39% |
| 2025 | $8.50 | $3.48 | -59% |
| 2026 YTD | $3.48 | $1.10 | -68% |
CNCK has finished every year since 2024 lower, and it's down 68% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over CNCK on returns for 2026, with the stronger performance.